Latest news and press releases about Arvinas, Inc. (ARVN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates.
Price
| Price | $8.16 |
| Market Cap | $526M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 39.84 |
| Price / Book | 0.87 |
| EV / EBITDA | 164.10 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 1.91% |
| Return on Invested Capital | -2.18% |
| Return on Assets | 1.38% |
| Gross Margin | 96.43% |
| Operating Margin | -4.45% |
| Net Margin | 2.94% |
Related companies: ATXS · AVBP · DAWN · DNA · ERAS · GERN · IOVA
Explore sector: Healthcare · Biotechnology
More sections of ARVN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks